Search

Your search keyword '"Cerretti, R"' showing total 181 results
Start Over Author "Cerretti, R"
181 results on '"Cerretti, R"'

1. Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial

Author

Venditti, A, Piciocchi, A, Candoni, A, Arena, V, Palmieri, R, Fili, C, Carella, A, Calafiore, V, Cairoli, R, De Fabritiis, P, Storti, G, Salutari, P, Lanza, F, Martinelli, G, Curti, A, Luppi, M, Ingrosso, C, Martelli, M, Cuneo, A, Albano, F, Mule, A, Tafuri, A, Cudillo, L, Tieghi, A, Fracchiolla, N, Capelli, D, Trisolini, S, Alati, C, La Sala, E, Maurillo, L, Del Principe, M, Consalvo, M, Divona, M, Ottone, T, Cerretti, R, Sconocchia, G, Voso, M, Fazi, P, Vignetti, M, Buccisano, F, Venditti A., Piciocchi A., Candoni A., Arena V., Palmieri R., Fili C., Carella A. M., Calafiore V., Cairoli R., De Fabritiis P., Storti G., Salutari P., Lanza F., Martinelli G., Curti A., Luppi M., Ingrosso C., Martelli M. P., Cuneo A., Albano F., Mule A., Tafuri A., Cudillo L., Tieghi A., Fracchiolla N. S., Capelli D., Trisolini S. M., Alati C., La Sala E., Maurillo L., Del Principe M. I., Consalvo M. A. I., Divona M. D., Ottone T., Cerretti R., Sconocchia G., Voso M. T., Fazi P., Vignetti M., Buccisano F., Venditti, A, Piciocchi, A, Candoni, A, Arena, V, Palmieri, R, Fili, C, Carella, A, Calafiore, V, Cairoli, R, De Fabritiis, P, Storti, G, Salutari, P, Lanza, F, Martinelli, G, Curti, A, Luppi, M, Ingrosso, C, Martelli, M, Cuneo, A, Albano, F, Mule, A, Tafuri, A, Cudillo, L, Tieghi, A, Fracchiolla, N, Capelli, D, Trisolini, S, Alati, C, La Sala, E, Maurillo, L, Del Principe, M, Consalvo, M, Divona, M, Ottone, T, Cerretti, R, Sconocchia, G, Voso, M, Fazi, P, Vignetti, M, Buccisano, F, Venditti A., Piciocchi A., Candoni A., Arena V., Palmieri R., Fili C., Carella A. M., Calafiore V., Cairoli R., De Fabritiis P., Storti G., Salutari P., Lanza F., Martinelli G., Curti A., Luppi M., Ingrosso C., Martelli M. P., Cuneo A., Albano F., Mule A., Tafuri A., Cudillo L., Tieghi A., Fracchiolla N. S., Capelli D., Trisolini S. M., Alati C., La Sala E., Maurillo L., Del Principe M. I., Consalvo M. A. I., Divona M. D., Ottone T., Cerretti R., Sconocchia G., Voso M. T., Fazi P., Vignetti M., and Buccisano F.

Published
2024

3. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System

Author

Della Porta, M G, Jackson, C H, Alessandrino, E P, Rossi, M, Bacigalupo, A, van Lint, M T, Bernardi, M, Allione, B, Bosi, A, Guidi, S, Santini, V, Malcovati, L, Ubezio, M, Milanesi, C, Todisco, E, Voso, M T, Musto, P, Onida, F, Iori, A P, Cerretti, R, Grillo, G, Molteni, A, Pioltelli, P, Borin, L, Angelucci, E, Oldani, E, Sica, S, Pascutto, C, Ferretti, V, Santoro, A, Bonifazi, F, Cazzola, M, and Rambaldi, A

Published
2017
Full Text
View/download PDF

4. Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia

Author

Buccisano, F, Maurillo, L, Piciocchi, A, Del Principe, M I, Picardi, A, Cerretti, R, Cudillo, L, De Angelis, G, Sarlo, C, Cefalo, M, Ditto, C, Di Veroli, A, Mariotti, B, Nasso, D, De Bellis, E, Del Poeta, G, Voso, M T, Sconocchia, G, Lo Coco, F, Arcese, W, Amadori, S, and Venditti, A

Published
2017
Full Text
View/download PDF

7. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor

Author

Cerva, C., Colagrossi, L., Maffongelli, G., Salpini, R., Di Carlo, D., Malagnino, V., Battisti, A., Ricciardi, A., Pollicita, M., Bianchi, A., Picardi, A., Cudillo, L., Cerretti, R., De Angelis, G., Cantonetti, M., Andreoni, M., Perno, C.F., Arcese, W., Svicher, V., and Sarmati, L.

Published
2016
Full Text
View/download PDF

9. Characterization ofFLT3-ITD(mut)acute myeloid leukemia: molecular profiling of leukemic precursor cells

Author

Travaglini, S, Angelini, DF, Alfonso, V, Guerrera, G, Lavorgna, S, Divona, M, Nardozza, AM, Consalvo, MI, Fabiani, E, De Bardi, M, Neri, B, Forghieri, F, Marchesi, F, Paterno, G, Cerretti, R, Barragan, E, Fiori, V, Dominici, S, Del Principe, MI, Venditti, A, Battistini, L, Arcese, W, Lo-Coco, F, Voso, MT, and Ottone, T

Subjects
body regions, psychological phenomena and processes
Abstract

Acute myeloid leukemia (AML) withFLT3-ITD mutations (FLT3-ITDmut) remains a therapeutic challenge, with a still high relapse rate, despite targeted treatment with tyrosine kinase inhibitors. In this disease, the CD34/CD123/CD25/CD99+ leukemic precursor cells (LPCs) phenotype predicts forFLT3-ITD-positivity. The aim of this study was to characterize the distribution ofFLT3-ITD mutation in different progenitor cell subsets to shed light on the subclonal architecture ofFLT3-ITD(mut)AML. Using high-speed cell sorting, we sequentially purified LPCs and CD34+ progenitors in samples from patients withFLT3-ITD(mut)AML (n = 12). A higherFLT3-ITD(mut)load was observed within CD34/CD123/CD25/CD99+ LPCs, as compared to CD34+ progenitors (CD123+/-,CD25-,CD99low/-) (p = 0.0005) and mononuclear cells (MNCs) (p < 0.0001). This was associated with significantly increased CD99 mean fluorescence intensity in LPCs. Significantly higherFLT3-ITD(mut)burden was also observed in LPCs of AML patients with a smallFLT3-ITD(mut)clones at diagnosis. On the contrary, the mutation burden of other myeloid genes was similar in MNCs, highly purified LPCs and/or CD34+ progenitors. Treatment with an anti-CD99 mAb was cytotoxic on LPCs in two patients, whereas there was no effect on CD34+ cells from healthy donors. Our study shows thatFLT3-ITD mutations occur early in LPCs, which represent the leukemic reservoir. CD99 may represent a new therapeutic target inFLT3-ITD(mut)AML.

Published
2020

25. Molecular expression of bone marrow angiogenic factors, cell-cell adhesion molecules and matrix-metallo-proteinases in plasmacellular disorders: A molecular panel to nvestigate disease progression

Author

Rapanotti, Mc, Franceschini, L, Suarez Viguria, Tm, Ialongo, C, Fraboni, D, Cerretti, R, De Angelis, G, Pupo, L, Rizzo, M, Cantonetti, M, Postorino, M, Voso, Mt, and Lo-Coco, F

Subjects
0301 basic medicine, Angiogenesis, Multiple Myeloma progression, Cell, Matrix-metalloproteinase, Matrix metalloproteinase, 03 medical and health sciences, 0302 clinical medicine, MCAM/MUC/ CD146, Angiogenic markers, Cell-cell-adhesion molecules, E-cadherin, Multiple myeloma progression, ECadherin, medicine, Multiple myeloma, E-Cadherin, Cadherin, Cell adhesion molecule, business.industry, lcsh:RC633-647.5, Hematology, lcsh:Diseases of the blood and blood-forming organs, medicine.disease, 030104 developmental biology, Infectious Diseases, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Cancer research, CD146, Bone marrow, business, Scientific Letter, Settore MED/15 - Malattie del Sangue
Abstract

Increasing levels of angiogenesis play an important role in the pathogenesis and progression of multiple myeloma (MM). Malignant plasma cells promote a gradual increase in the degree of angiogenesis, modulation of specific cell-cell adhesion molecules and secretion of matrix-metallo-proteinases (MMPs), changing the BM composition from benign conditions, such as MGUS, to smouldering multiple myeloma (SM) and to active MM. We aimed to identify a gene expression profile, helpful to discriminate the “angiogenic potential” in BM and PB plasma cells from MGUS, SMM and active MM patients analyzed at diagnosis. We analyzed the expression of cell-cell adhesion molecules such as VE-Cadherin, E-Cadherin MCAM/MUC18/CD146 and of the MMP-2 and MMP-9. MCAM/MUC18 expression resulted mostly associated with that of the pivotal angiogenic factors VEGF and Ang2, and in MGUS the pattern was different in steady state, compared to progression towards SM. Furthermore, E-Cadherin, the main epithelial cell-cell-adhesion molecule, unexpectedly resulted overexpressed in MM.

Published
2018

26. PS1011 MEASURABLE RESIDUAL DISEASE BY MULTIPARAMETRIC FLOW-CYTOMETRY IS A RELIABLE TOOL FOR RISK-STRATIFICATION OF FLT3-MUTATED AML PATIENTS

Author

Palmieri, R., primary, Maurillo, L., additional, Principe, M.I. Del, additional, Veroli, A. Di, additional, Paterno, G., additional, Bellis, E. De, additional, Cerretti, R., additional, Angelis, G. De, additional, Mariotti, B., additional, Ottone, T., additional, Divona, M., additional, Lavorgna, S., additional, Consalvo, M.A. Irno, additional, Conti, C., additional, Attrotto, C., additional, Fraboni, D., additional, Voso, M.T., additional, Amadori, S., additional, Coco, F. Lo, additional, Arcese, W., additional, Venditti, A., additional, and Buccisano, F., additional

Published
2019
Full Text
View/download PDF

28. Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia

Author

Buccisano, F, primary, Maurillo, L, additional, Piciocchi, A, additional, Del Principe, M I, additional, Picardi, A, additional, Cerretti, R, additional, Cudillo, L, additional, De Angelis, G, additional, Sarlo, C, additional, Cefalo, M, additional, Ditto, C, additional, Di Veroli, A, additional, Mariotti, B, additional, Nasso, D, additional, De Bellis, E, additional, Del Poeta, G, additional, Voso, M T, additional, Sconocchia, G, additional, Lo Coco, F, additional, Arcese, W, additional, Amadori, S, additional, and Venditti, A, additional

Published
2016
Full Text
View/download PDF

29. Allogeneic Transplant in Acute Myeloid Leukemia (AML) According to the Policy of the Rome Transplant Network (RTN): An Intention-to-Treat Analysis

Author

Arcese, W., Amadori, S., Cerretti, R., Cudillo, L., Angelis, G., Venditti, A., Buccisano, F., Cantonetti, M., Mangione, I., Andreani, M., Testi, M., Rapanotti, M. C., Fabritiis, P., Dentamaro, T., Cupelli, L., Tendas, A., Tirindelli, M. C., Annibali, O., Saltarelli, F., Mengarelli, A., Marchesi, F., Gumenyuk, S., Chierichini, A., Anaclerico, B., agostino tafuri, Montefusco, E., Ferrari, A., Naso, V., Di Piazza, F., and Picardi, A.

Published
2015

30. Unique Chemotherapy Based Reduced Intensity Conditioning Regimen for Patients Transplanted from HLA Identical Siblings, Haploidentical or Volunteer Unrelated Donors: a Prospective Study from the Rome Transplant Network

Author

Cerretti, R., Picardi, A., Cudillo, L., Angelis, G., Mariotti, B., Mengarelli, A., Marchesi, F., Mangione, I., Testi, M., Fabritiis, P., Dentamaro, T., Tirindelli, M. C., Saltarelli, F., Chierichini, A., Anaclerico, B., agostino tafuri, Ferrari, A., Di Piazza, F., and Arcese, W.

Published
2015

31. Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia

Author

Maurillo, L, Buccisano, F, Piciocchi, A, DEL PRINCIPE, Mi, Sarlo, C, Di Veroli, A, Panetta, P, Irno Consalvo, M, Nasso, D, Ditto, C, Refrigeri, M, De Angelis, G, Cerretti, R, Arcese, W, Sconocchia, G, LO COCO, F, Amadori, S, and Venditti, A

Subjects
MRD, AML, genetic structures, ARAC, Settore MED/15 - Malattie del Sangue
Abstract

[object Object]

Published
2015
Full Text
View/download PDF

34. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Author

Alessandrino, Ep, Porta, Mg, Malcovati, L, Jackson, Ch, Pascutto, C, Bacigalupo, A, Teresa van Lint, M, Falda, M, Bernardi, M, Onida, F, Guidi, S, Iori, Ap, Cerretti, R, Marenco, P, Pioltelli, P, Angelucci, E, Oneto, R, Ripamonti, F, Rambaldi, A, Bosi, A, Cazzola, M, Gruppo Italiano Trapianto di Midollo Osseo Levis, A, Bandini, G, Casini, M, Rossi, G, Baronciani, D, La Nasa, G, Milone, G, Mordini, N, Van Lint MT, Corradini, P, Milani, R, Morra, E, Lambertenghi Deliliers, G, Ciceri, F, Castagna, L, Narni, F, Selleri, C, Scime, R, Iannitto, E, Musso, M, Locatelli, F, Zecca, M, Martelli, F, Visani, G, Di Bartolomeo, P, Cavanna, L, Papineschi, Federico, Messina, G, Merli, F, Foa, R, Locasciulli, A, Majolino, I, Chiusolo, P, Leone, G, Arcese, W, Carella, Am, Cascavilla, N, Mazza, P, Bruno, B, Boccadoro, M, Fanin, R, Cerno, M, Bortolo, S, and Author information, Raimondi R.

Subjects
Oncology, Adolescent, Adult, Aged, Aged, 80 and over, Child, Cohort Studies, Female, Humans, Male, Markov Chains, Middle Aged, Myelodysplastic Syndromes, Risk, Survival Analysis, Time Factors, Transplantation, Homologous, Hematopoietic Stem Cell Transplantation, Hematology, Homologous, medicine.medical_specialty, Allogeneic transplantation, medicine.medical_treatment, Hematopoietic stem cell transplantation, Natural history of disease, Internal medicine, medicine, 80 and over, Survival analysis, Transplantation, business.industry, Myelodysplastic syndromes, Original Articles, medicine.disease, Settore MED/15, Surgery, allogeneic transplantation, International Prognostic Scoring System, Risk assessment, business
Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Registry studies have shown that advanced disease stage at transplantation is associated with inferior overall survival. To define the optimal timing of allogeneic HSCT, we carried out a decision analysis by studying 660 patients who received best supportive care and 449 subjects who underwent transplantation. Risk assessment was based on both the International Prognostic Scoring System (IPSS) and the World Health Organization classification-based Prognostic Scoring System (WPSS). We used a continuous-time multistate Markov model to describe the natural history of disease and evaluate the effect of allogeneic HSCT on survival. This model estimated life expectancy from diagnosis according to treatment policy at different risk stages. Relative to supportive care, estimated life expectancy increased when transplantation was delayed from the initial stages until progression to intermediate-1 IPSS-risk or to intermediate WPSS-risk stage, and then decreased for higher risks. Modeling decision analysis on WPSS versus IPSS allowed better estimation of the optimal timing of transplantation. These observations indicate that allogeneic HSCT offers optimal survival benefits when the procedure is performed before MDS patients progress to advanced disease stages. Am. J. Hematol. 88:581–588, 2013. © 2013 Wiley Periodicals, Inc.

Published
2013

40. Bone Marrow Angiogenic Potential and Molecular Expression of Cell-Cell Adhesion Molecules and Matrix-Metallo Proteinases in Multiple Myeloma

Author

Rapanotti, M.C., primary, Franceschini, L., additional, Suarez Viguria, T.M., additional, Ialongo, C., additional, Vaccarini, S., additional, Rizzo, M., additional, Cicconi, L., additional, Onnis, I., additional, Meconi, F., additional, Cerretti, R., additional, De Angelis, G., additional, Mariotti, B., additional, Pupo, L., additional, Cantonetti, M., additional, Postorino, M., additional, and Lo-Coco, F., additional

Published
2015
Full Text
View/download PDF

41. The potential application of the allogeneic transplant according to a widespread donor search policy: an intention-to-treat analysis from the Rome Transplant Network

Author

Picardi, A, DE FABRITIIS, P, Dentamaro, T, De Rossi, G, Caniglia, M, Petti, M, Mengarelli, A, Annino, L, Chierichini, A, Monarca, B, Ferrari, A, Avvisati, G, Tirindelli, M, Mangione, I, Pinto, R, Montefusco, E, Annibali, O, Cupelli, L, Cudillo, L, Cerretti, R, De Angelis, G, Giannotti, F, Di Veroli, A, Provenzano, I, Mirabile, M, and Arcese, W

Subjects
Settore MED/15 - Malattie del Sangue
Published
2010

43. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation

Author

Crocchiolo, R., Zino, E., Vago, L., Oneto, R., Bruno, B., Pollichieni, S., Sacchi, N., Sormani, M. P., Marcon, J., Lamparelli, T., Fanin, R., Garbarino, L., Miotti, V., Bandini, G., Bosi, A., Ciceri, F., Bacigalupo, A., Fleischhauer, K., Midollo Osseo Gruppo Italiano Trapianto, D. I., Terapia Cellulare, Cellule Staminali Ematopoietiche Cse E., Italian Bone Marrow Donor Registry Collaboratori, Scalari P., Bontempelli, M., Prinoth, O., Carcassi, C., Marceno, R., Porfirio, Rombola, G., Lombardo, Ferrioli, G., Poli, F., Scalamogna, M., Mazzi, B., Rossi, F., Mascaretti, L., Albergoni, Salvaneschi, L., Salvaneschi, M., Valentini, Nesci, S., Papola, F., Scatena, Mariotti, Perrone, Laurenti, Grammatico, Paola, Mariani, M., Favoino, B., Guizzardi, Pontiero, Leoni, P., Rambaldi, A., Casini, M., Angelucci, E., Baronciani, D., La Nasa, G., Milone, G., Guidi, S., Van Lint, M. T., Dini, G., Corradini, P., Milani, R., Morra, E., Marenco, P., Deliliers, Lambretenghi G., Onida, F., Marcatti, M., Castagna, L., Pioltelli, P., Selleri, C., Zanesco, L., Scime, R., Musso, M., Alessandrino, E. P., Locatelli, F., Visani, G., Di Bartolomeo, P., Papineschi, F., Favre, C., Iori, A. P., Foa, Roberto, Locasciulli, A., Majolino, I., Majolino, P., Leone, G., Arcese, W., Cerretti, R., Carella, A. M., Cascavilla, N., Lauria, F., Mazza, P., Cerno, M., Benedetti, F., Crocchiolo, R, Zino, E, Vago, L, Oneto, R, Bruno, B, Pollichieni, S, Sacchi, N, Sormani, Mp, Marcon, J, Lamparelli, T, Fanin, R, Garbarino, L, Miotti, V, Bandini, G, Bosi, A, Ciceri, F, Bacigalupo, A, and Fleischhauer, K

Subjects
Adult, Disease-Free Survival, Donor Selection, Female, HLA-DRB1 Chains, Hematologic Neoplasms, Humans, Italy, Male, Middle Aged, Recurrence, Registries, Retrospective Studies, Risk Factors, Survival Rate, Transplantation, Homologous, Algorithms, HLA-DR Antigens, Hematopoietic Stem Cell Transplantation, Tissue Donors, Biochemistry, Immunology, Hematology, Cell Biology, Homologous, medicine.medical_treatment, Human leukocyte antigen, Hematopoietic stem cell transplantation, Medicine, Risk factor, Survival rate, Transplantation, HLA-DPB1, business.industry, Hazard ratio, Confidence interval, business, Settore MED/15 - Malattie del Sangue
Abstract

The importance of donor-recipient human leukocyte antigen (HLA)-DPB1 matching for the clinical outcome of unrelated hematopoietic stem cell transplantation (HSCT) is controversial. We have previously described an algorithm for nonpermissive HLA-DPB1 disparities involving HLA-DPB1*0901,*1001,*1701,*0301,*1401,*4501, based on T-cell alloreactivity patterns. By revisiting the immunogenicity of HLA-DPB1*02, a modified algorithm was developed and retrospectively tested in 621 unrelated HSCTs facilitated through the Italian Registry for onco-hematologic adult patients. The modified algorithm proved to be markedly more predictive of outcome than the original one, with significantly higher KaplanMeier probabilities of 2-year survival in permissive compared with nonpermissive transplantations (55% vs 39%, P = .005). This was the result of increased adjusted hazards of nonrelapse mortality (hazard ratio [HR] = 1.74; confidence interval [CI], 1.19-2.53; P = .004) but not of relapse (HR = 1.02; CI, 0.73-1.42; P = .92). The increase in the hazards of overall mortality by nonpermissive HLA-DPB1 disparity was similar in 10 of 10 (HR = 2.12; CI, 1.23-3.64; P = .006) and 9 of 10 allele-matched transplantations (HR = 2.21; CI, 1.28-3.80; P = .004), both in early-stage and in advanced-stage disease. These data call for revisiting current HLA matching strategies for unrelated HSCT, suggesting that searches should be directed up-front toward identification of HLA-DPB1 permissive, 10 of 10 or 9 of 10 matched donors. (Blood. 2009; 114:1437-1444) RI Porfirio, Berardino/I-1988-2012

Published
2009

45. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation

Author

Crocchiolo, R, Zino, E, Vago, L, Oneto, R, Bruno, B, Pollichieni, S, Sacchi, N, Sormani, Mp, Marcon, J, Lamparelli, T, Fanin, R, Garbarino, L, Miotti, V, Bandini, G, Bosi, A, Ciceri, F, Bacigalupo, A, Fleischhauer, K, Gruppo Italiano Trapianto di Midollo Osseo, Terapia Cellulare, Cellule Staminale Ematopoietiche e., Italian Bone Marrow Donor Registry, Scalari, P, Bontempelli, M, Prinoth, O, Carcassi, C, Marcenò, R, Porfirio, Rombolà, G, Lombardo, Ferrioli, G, Poli, F, Scalamogna, M, Mazzi, B, Rossi, F, Mascaretti, L, Albergoni, Salvaneschi, L, Martinetti, M, Valentini, Renzo, Nesci, S, Papola, F, Scatena, Mariotti, Perrone, Laurenti, Grammatico, P, Mariani, M, Favoino, B, Guizzardi, Pontiero, Leoni, P, Rambaldi, A, Casini, M, Angelucci, E, Baronciani, D, La Nasa, G, Milone, G, Guidi, S, Van Lint MT, Dini, G, Corradini, P, Milani, R, Morra, E, Marenco, P, Lambretenghi Deliliers, G, Onida, F, Marcatti, M, Castagna, L, Pioltelli, P, Selleri, C, Zanesco, L, Scimè, R, Musso, M, Alessandrino, Ep, Locatelli, F, Visani, G, Di Bartolomeo, P, Papineschi, Federico, Favre, C, Iori, Ap, Foà, R, Locasciulli, A, Majolino, I, Majolino, P, Leone, G, Arcese, W, Cerretti, R, Carella, Am, Cascavilla, N, Lauria, F, Mazza, P, Cerno, M, and Benedetti, F.

Published
2009

46. The policy of the Rome Transplant Network (RTN), a metropolitan (2009). The Potential Application Of The Allogeneic Transplant By The Policy Of Widespread Donor Search: An Intention-To-Treat Analysis From The Rome Transplant Network

Author

Picardi, A, DE FABRITIIS, P, Dentamaro, T, De Rossi, G, Caniglia, M, Pinto Petti, M, Mengarelli, A, Annino, L, Chierichini, Monarca, B, Montefusco, E, Avvisati, G, Tirindelli, M, Mangione, I, Cudillo, L, Cerretti, R, De Angelis, G, Di Veroli, A, Provenzano, I, and Arcese, W

Subjects
Settore MED/15 - Malattie del Sangue
Published
2009

49. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome : a study from the Gruppo Italiano Trapianto di Midollo Osseo(GITMO)

Author

Alessandrino, Ep, Della Porta MG, Bacigalupo, A, Van Lint MT, Falda, M, Onida, F, Bernardi, M, Iori, Ap, Rambaldi, A, Cerretti, R, Marenco, P, Pioltelli, P, Malcovati, L, Pascutto, C, Oneto, R, Fanin, R, Bosi, A, Collaboratori Levis, A, Bandini, G, Casini, M, Rossi, G, Angelucci, E, Baronciani, D, La Nasa, G, Milone, G, Mordini, N, Guidi, S, Corradini, P, Milani, R, Morra, E, Lambretenghi Deliliers, G, Ciceri, F, Castagna, L, Narni, F, Selleri, C, Scimè, R, Iannitto, E, Musso, M, Locatelli, F, Martelli, F, Visani, G, Di Bartolomeo, P, Cavanna, L, Papineschi, F, Messina, G, Gugliotta, L, Foà, R, Locasciulli, A, Majolino, I, Chiusolo, P, Leone, G, Arcese, W, Carella, Am, Cascavilla, N, Mazza, P, Bruno, Benedetto, Boccadoro, Mario, Cerno, M, and Raimondi, R.

Subjects
Adult, Male, medicine.medical_specialty, Blood transfusion, Adolescent, medicine.medical_treatment, Immunology, World Health Organization, Biochemistry, Gastroenterology, Humans, Myelodysplastic Syndromes, Prognosis, Aged, Recurrence, Survival Rate, Classification, Blood Transfusion, Hematopoietic Stem Cell Transplantation, Middle Aged, Female, Refractory, hemic and lymphatic diseases, Internal medicine, medicine, Survival rate, Acute leukemia, Hematology, business.industry, Cancer, Cell Biology, medicine.disease, Surgery, Transplantation, Who classification, business, Settore MED/15 - Malattie del Sangue
Abstract

We evaluated the impact of World Health Organization (WHO) classification and WHO classification–based Prognostic Scoring System (WPSS) on the outcome of patients with myelodysplastic syndrome (MDS) who underwent allogeneic stem cell transplantation (allo-SCT) between 1990 and 2006. Five-year overall survival (OS) was 80% in refractory anemias, 57% in refractory cytopenias, 51% in refractory anemia with excess blasts 1 (RAEB-1), 28% in RAEB-2, and 25% in acute leukemia from MDS (P = .001). Five-year probability of relapse was 9%, 22%, 24%, 56%, and 53%, respectively (P < .001). Five-year transplant-related mortality (TRM) was 14%, 39%, 38%, 34%, and 44%, respectively (P = .24). In multivariate analysis, WHO classification showed a significant effect on OS (P = .017) and probability of relapse (P = .01); transfusion dependency was associated with a reduced OS (P = .01) and increased TRM (P = .037), whereas WPSS showed a prognostic significance on both OS (P = .001) and probability of relapse (P < .001). In patients without excess blasts, multilineage dysplasia and transfusion dependency affected OS (P = .001 and P = .009, respectively), and were associated with an increased TRM (P = .013 and P = .031, respectively). In these patients, WPSS identified 2 groups with different OS and TRM. These data suggest that WHO classification and WPSS have a relevant prognostic value in posttransplantation outcome of MDS patients.

Published
2008

50. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Author

Alessandrino, Ep, Della Porta MG, Bacigalupo, A, Van Lint MT, Falda, M, Onida, F, Bernardi, M, Iori, Ap, Rambaldi, A, Cerretti, R, Marenco, P, Pioltelli, P, Malcovati, L, Pascutto, C, Oneto, R, Fanin, R, Bosi, A, Gruppo Italiano Trapianto di Midollo Osseo, Levis, A, Bandini, G, Casini, M, Rossi, G, Angelucci, E, Baronciani, D, La Nasa, G, Milone, G, Mordini, N, Guidi, S, Corradini, P, Milani, R, Morra, E, Lambretenghi Deliliers, G, Ciceri, F, Castagna, L, Narni, F, Selleri, C, Scimè, R, Iannitto, E, Musso, M, Locatelli, F, Martelli, F, Visani, G, Di Bartolomeo, P, Cavanna, L, Papineschi, Federico, Messina, G, Gugliotta, L, Foà, R, Locasciulli, A, Majolino, I, Chiusolo, P, Leone, G, Arcese, W, Carella, Am, Cascavilla, N, Mazza, P, Bruno, B, Boccadoro, M, Cerno, M, and Raimondi, R.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results